Session Descriptions

9:15am-10:45am
Saturday April 28
Plenary/Awards
 
SCABB Award Lectures
Technical/Scientific Award Lecture:  Blood group diversity and its impact on transfusion medicine, ​Geoff Daniels BSc, PhD, FRCPath  Blood group antigens exhibit a wide structural diversity, including peptide antigens on proteins and carbohydrate epitopes on glycoproteins and/or glycolipids. Glycoproteins are inserted within the membrane via single or multiple trans-membrane domains, or via glycosylphosphatidylinositol linkages. Blood group antigens provide a variety of physiological functions, including membrane transport, adhesion and receptor functions, enzyme activity, complement regulation, anchoring the membrane to the cytoskeleton, and contributing to the glycocalyx. This presentation will also review the diversity of blood group antibodies in relation to their clinical importance in haemolytic transfusion reactions and haemolytic disease of the fetus and newborn.

Administrative Award Lecture:  Disrupt or be Disrupted - How to bring new ideas into your organization.  George "Bud" Scholl  OneBlood has built a reputation on being innovative and entreprenuerial in a highly regulated environment. Learn how OneBlood goes about incubating new ideas and turning them into new initiatives and businesses. 
 

10:45am-11:45am
Saturday April 28
Plenary/Awards
 
Karen Williams Memorial Lecturer 
KWML Award Lecturer:  Transfusion-associated Bacterial Sepsis,  Richard J. Benjamin MBChB, PhD.  Bacterial sepsis remains the most common transfusion-related infection. Even with optimum skin cleansing, sample diversion and culture screening, 1:1,000-1:2,500 platelets contain viable bacteria. Low bacterial numbers not detected by culture can grow to life-threatening concentrations during storage. FDA draft guidance recommends additional interventions, including delayed re-culture, point of issue testing or pathogen reduction. Following discussions at a FDA BPAC meeting in November 2017, additional options are being considered, including anaerobic cultures, delayed sampling and enlarged volumes. Hemovigilance reports from the UK, Switzerland, Belgium and France are instructive. This presentation will comment on the options available to further protect patients. 
1:15pm-3:30pm
Saturday April 28
AIMS
 
RH System Genotyping & Discrepancy Resolutions
RHD Genotyping: Resolving Discrepancies and Assessing Risk, Margaret Keller, PhD
A joint statement released in 2015 from AABB, the American Red Cross and several other organizations found the use of RHD genotyping to be a feasible and appropriate first step for more precise decision-making in obstetrical practice and transfusion medicine. This lecture will provide the rationale for the use of RHD genotyping to determine which patients with a serologic weak D phenotype require Rh immunoglobulin and also how this testing can resolve typing discrepancies. We will review one hospitals approach to determine which patient cases would benefit from RHD genotyping.

Pass Interference: DNA Changes to RHCE Genes, Katrina Billingsley, MT(ASCP) SBB, Monica Kalvelage, MT(ASCP) MB, SBB

This session takes a football themed approach to the RHD and RHCE proteins. What are the causes of RHCE partial antigens and how do transfusion services handle the antibodies these patients can make.

Identification of RH variants that encode D-like and CE-like antigens, Gorka Ochoa, PhD 
Description of the molecular basis of RHD variants that encode RhCE antigens and RHCE variants that encode RhD antigens.
Intended Audience:: Blood bank & transfusion services personnel



3:45pm-5:45pm
Saturday April 28
AIMS
 
Next Generation Sequencing & Case Studies #1
Automated clinical typing of red blood cell antigens using next generation sequencing, William Lane, MD PhD
With the emergence of genomic approaches and personalized medicine, Next Generation Sequencing (NGS) data can now be used to evaluate genes encoding RBC antigens to type for antigens with a known molecular basis. NGS based typing can allow for more extensive characterization of patient and donor phenotypes and enable enhanced blood product selection and identification of donors with rare phenotypes. 

Case Studies with Audience Participation, Fernando Lerma, SBB(ASCP), Sandy Wortman, MT(ASCP)SBB, Virginia Reyes, MT(ASCP)SBB 
For the ultimate brain teasers come sit with colleagues as we take a closer look at a selection of complex immunohematology case studies. Utilizing serology and molecular genotyping technologies, these cases are sure to keep you on the edge of your seat.

8:30pm-9:30am
Sunday April 29
AIMS
 
John Moulds Memorial Lecture
Blood Group Genetics: Past, Present, and Future, Geoff Daniels, PhD FRCPath
For much of the twentieth century, blood groups contributed enormously to our understanding of human genetics. Later, blood group genes were identified and sequenced, and the molecular bases for the blood group polymorphisms were elucidated, making it possible to carry out extended blood grouping on DNA of patients and donors without the need for red cells. This includes blood grouping fetuses from fetal DNA in the mother’s blood. In the future more advanced technology will enhance the possibilities of performing all blood grouping by molecular methods. Could we be approaching the end of serological blood grouping?

9:30am-10:30am
Sunday April 29
AIMS
 
Training & Competency Asssesments
Training & Competency Assessment Programs in the IRL: A Full Time Job, Sandy Wortman, MT(ASCP)SBB, Tobie Kaufman, MT(ASCP)SBB
All laboratories are feeling the pressure of making sure all six of the CLIA competency assessment pillars are being meet each year. This has become a huge challenge particularly for AABB accredited Immunohematology Reference Laboratories (IRLs). Come get ideas and listen to how the Carter BloodCare IRL and the Blood Systems IRL each decided how they were going to develop their training and competency programs in order to meet the CLIA requirements. 

10:45am-12:15pm
Sunday April 29
AIMS
 
Providing Platelets to the Refractory Patient: Where To Begin?
Evolving Strategies for Providing Functional Platelets in the Refractory Patient, Kevin Land, MD
This interactive presentation will be a practical overview of the primary topics that should be considered when there is a patient who appears refractory to regular apheresis platelets. 

Patient Refractory? Where Do I Start?, Stan Hance, MT(ASCP) 
Review options for finding most compatible platelets for Refractory Patients.
    

Platelet Antibodies: A Clinical Perspective, Hank Hanna, MD
We will discuss some of the strategies used to transfuse platelets to refractory patients.
1:30am-3:30pm
Sunday April 29
AIMS
 
Asking the Experts & Blood Group Systems Overview
Ask the Experts, Geoff Daniels, PhD FRCPath, Kevin Land, MD, Margaret Keller, PhD, Hank Hanna, MD, Gorka Ochoa MD, PhD, William Lane, MD PhD  

Blood Group Antigens and Allele Nomenclature, Virginia Reyes, MT(ASCP) SBB, Michael Gannett, MLS(ASCP)
With the discovery of new alleles and the reclassifying of some antigens into new or older blood group systems, it is prudent to review the changes. Molecular testing has created new nomenclature which must be considered when speaking and writing.   
    

Blood Group and Allele Nomenclature, Michael Gannett, MLS(ASCP)SBB 
With the discovery of new alleles and the reclassifying of some antigens into new or older blood group systems, it is prudent to review the changes. Molecular testing has created new nomenclature which must be considered when speaking and writing.

Molecular Methods and their Limitations, Michael Gannett, MLS(ASCP)SBB 
With the commonplace use of molecular testing to predict blood group antigens, it is important that the limitations of the methods be known by those utilizing the results in complex antibody investigations to ensure the safety of patients. This session will review the common molecular methods, limitations, and cases of discrepancies between serology and molecular testing.

Blood Group System Review- Kell System, Lorena Aranda, MSHS, SBB(ASCP)
This presentation will be an overview of the Kell Blood Group System. We will discuss the prevalence of the Kell antigens and their clinical significance.  
3:45pm-4:45pm
Sunday April 29
AIMS
 
Case Studies #2
Case Study #1, Margaret Keller, PhD 
Use a series of patient cases that were solved using advanced serologic and molecular approaches.
Case Study #2, Sandy Wortman, MT(ASCP)SBB
For the ultimate brain teasers come sit with colleagues as we take a closer look at a selection of complex immunohematology case studies. Utilizing serology and molecular genotyping technologies, these cases are sure to keep you on the edge of your seat.
Case Study #3, Katrina Billingsley, MT, (ASCP), SBB